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Maria J. Worsham, PhD; S. David Nathanson, MD; Patricia Miller, MD; Jessica M. Bensenhaver, MD;
Erica Proctor, MD; Monique Swain, MD; Christos Patriotis, PhD; Paul F. Engstrom, MD
IMPORTANCE Compared with white American (WA) women, African American (AA) women
have a 2-fold higher incidence of breast cancers that are negative for estrogen receptor,
progesterone receptor, and ERBB2 (triple-negative breast cancer [TNBC]). Triple-negative
breast cancer, compared with non-TNBC, likely arises from different pathogenetic pathways,
and benign breast disease (BBD) predicts future non-TNBC.
OBJECTIVE To determine whether AA identity remains associated with TNBC for womenwith
a prior diagnosis of BBD.
DESIGN, SETTING, AND PARTICIPANTS This study is a retrospective analysis of data of a cohort
of 2588 AA and 3566WAwomen aged between 40 and 70 years with a biopsy-proven BBD
diagnosis. The data—obtained from the Pathology Information System of Henry Ford Health
System (HFHS), an integratedmultihospital andmultispecialty health care system
headquartered in Detroit, Michigan—include specimens of biopsies performed between
January 1, 1994, and December 31, 2005. Data analysis was performed fromNovember 1,
2015, to June 15, 2016.
MAIN OUTCOMES ANDMEASURES Subsequent breast cancer was stratified on the basis of
combinations of hormone receptor and ERBB2 expression.
RESULTS Casemanagement, follow-up, and outcomes received or obtained by our cohort of
2588 AA and 3566WA patients were similar, demonstrating that HFHS delivered care
equitably. Subsequent breast cancers developed in 103 (4.1%) of AA patients (mean follow-up
interval of 6.8 years) and 143 (4.0%) of WA patients (mean follow-up interval of 6.1 years).
More than three-quarters of subsequent breast cancers in each subset were ductal carcinoma
in situ or stage I. The 10-year probability estimate for developing TNBCwas 0.56% (95% CI,
0.32%-1.0%) for AA patients and 0.25% (95% CI, 0.12%-0.53%) for WA patients. Among the
66 AA patients who developed subsequent invasive breast cancer, 16 (24.2%) developed
TNBC compared with 7 (7.4%) of the 94WA patients who developed subsequent invasive
breast cancers and had complete biomarker data (P = .01).
CONCLUSIONS AND RELEVANCE This study is the largest analysis to date of TNBC in the
context of racial/ethnic identity and BBD as risk factors. The study found that AA identity
persisted as a significant risk factor for TNBC. This finding suggests that AA identity is
associated with inherent susceptibility for TNBC pathogenetic pathways.
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I ncidence of triple-negative breast cancer (TNBC),which isnegative for the estrogen receptor (ER), the progesteronereceptor (PR), andERBB2, is 2-foldhigher inAfricanAmeri-
can (AA) women than in white American (WA) women.1
Most TNBC belongs to the inherently aggressive basal
subtypeandarises fromdifferentpathogeneticpathwayscom-
pared to non-TNBC.2,3 Benign breast disease (BBD) is associ-
ated with increased risk for ER-positive/non-TNBC.4,5 In this
study, we sought to determinewhether AA identity is associ-
ated with TNBC among a cohort of AA and WA women who
were initially diagnosed with BBD.
Methods
From January 1 through December 31, 2013, we queried the
HFHS Pathology Information System to identify AA and WA
womenpatients aged40 to70yearswhowerediagnosedwith
BBD by biopsy performed between January 1, 1994, and De-
cember 31, 2005. Patients with prior breast cancer were ex-
cluded. Patientswhose breast cancerwas diagnosedwithin 6
months of BBDbiopsywere excluded to avoid including cases
of coexisting BBD and cancer.
Self-reported race/ethnic identity, date of birth, and fol-
low-upwereobtainedfromelectronicmedical recordsatHFHS.
Invasive carcinoma or ductal carcinoma in situ detected dur-
ing follow-up was recorded as subsequent cancer.
An automated Dako immunostainer was used for ER/PR
staining. ERBB2 immunostaining was performed using Her-
cepTest (Dako). Immunohistochemistry complied with estab-
lished guidelines.6,7 Briefly, tumors with less than 1% nuclear
stainingwere scored as ER/PR-negative.ERBB2 grading (0-3+)
was based on the extent of membranous staining: 0 or 1+ was
negative; 3+waspositive. Tumorswith 2+ stainingunderwent
fluorescent insituhybridization.Benignbreastdiseasewasclas-
sified as fibrocystic/proliferative/hyperplasia without atypia,
with atypia, or with lobular carcinoma in situ.
Distributions of clinicopathologic variables between
AA and WA patients were compared using t test, Mantel-
Haenszel test, orWilcoxonranksumtest. Polychotomousmul-
tivariable logistic regression evaluated features that are asso-
ciatedwithTNBC.Kaplan-Meiermethodsgeneratedestimates
of breast cancer incidencewith log-rank P values. All statisti-
cal testswere2-sided, andanalyseswereperformedusingSAS,
version 9.3 (SAS Institute Inc), and known biomarker data.
The Henry Ford Health System (HFHS) Institutional
Review Board approved this research, with informed-
consent exemption. Data analysis was performed from
November 1, 2015, to June 15, 2016.
Results
The study cohort included 2588AApatients and 3566WApa-
tients. Mean age at BBD diagnosis was similar: 51.7 years for
AApatients and52.1 years forWApatients (P = .07).Mean fol-
low-up was also similar: 10.3 years for AA patients and 10.2
years for WA patients. (There was no follow-up for 36 [1.4%]
AA patients and 40 [1.1%] WA patients.) Benign breast dis-
ease biopsies evaluated screeningmammography abnormali-
ties in 2019 (78.0%) AA patients and 2800 (78.5%) WA pa-
tients; 555 (21.4%) AA patients and 748 (21.0%) WA patients
underwentbiopsy forclinical findings (P = .47).More than90%
of each subset had hyperplasia without atypia (2438 [94.2%]
in AA patients and 3283 [92.1%] in WA patients). Atypia was
more common among WA patients than among AA patients
(283 [7.9%]vs 150 [5.8%], respectively;P = .001). Three (0.1%)
patients in each subset had lobular carcinoma in situ.
Thirty (1.18%)AApatientsand30(0.85%)WApatientswere
diagnosedwith subsequent ductal carcinoma in situ (P = .26)
atmeanagesof 58.4years and61.8years, respectively (P = .16)
and atmean follow-up of 6.5 years and 6.1 years, respectively
(P = .64). The ER was positive in 86.4% of AA ductal carci-
noma in situ cases and 88.9% ofWA ductal carcinoma in situ
cases (P = .81). The PRwas positive in 77.3% of AA ductal car-
cinoma in situ cases and77.8%ofWAductal carcinoma in situ
cases (P = .97).
Subsequent invasive breast cancer was diagnosed in 73
(2.8%)AApatients and 111 (3.1%)WApatients (P = .58) at simi-
lar follow-up intervals and mean ages (Table 1). Approxi-
mately half of each subset was diagnosed with stage I dis-
ease. Triple-negative breast cancerwas detected in 3 times as
many AA patients as in WA patients (16 [24.2%] vs 7 [7.4%],
respectively; P = .01) with subsequent invasive breast cancer
(Table 2).
Polychotomous logistic regression (performed on 157 co-
hort members who developed subsequent breast cancer) re-
vealed thatAA identity andhigh-gradediseasewere the 2 sta-
tistically significant features associated with TNBC. African
American identity remainedsignificantlyassociatedwithTNBC
after adjusting for tumor grade. Among thosewhodeveloped
invasive breast cancer, the odds of TNBC vs ER/PR-positive/
HER2-negative was 4.34 times (95% CI, 1.28-14.68; P = .02)
higher in AA patients than inWA patients.
Kaplan-Meier riskestimatesare shownin theFigure. There
were no significant differences between AA patients andWA
patients when all phenotypes were grouped together (log-
rankP = .45),withanestimated10-year incidenceof2.5%(95%
Key Points
Question Does race/ethnicity affect breast cancer risk among
womenwith benign breast disease?
Findings A review of a cohort comprising 2588 African American
(AA) women and 3566white American (WA) womenwith
biopsy-proven benign breast disease revealed subsequent ductal
carcinoma in situ in 30 (1.18%) AA patients and 30 (0.85%)WA
patients and subsequent invasive cancer in 73 (2.8%) AA patients
and in 111 (3.1%)WA patients. Of the subsequent invasive cancers,
triple-negative breast cancer was more common among AA
members than amongWAmembers of the cohort (16 [24.2%] vs 7
[7.4%], respectively).
Meaning African American identity is a risk factor for
triple-negative breast cancer among womenwith benign breast
disease.
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CI, 1.9%-3.2%) and 3.2% (95% CI, 2.6%-4.0%), respectively.
Most subsequent invasive breast cancers were non-TNBC for
both AA andWA patients; however, risk of subsequent TNBC
was significantly higher for AA patients than for WA patients
(log-rank P = .004), and risk of subsequent non-TNBC was
higher forWApatients than forAApatients (log-rankP = .048).
Ten-year estimates for incidenceofTNBCwere0.56%(95%CI,
0.32%-1.0%) and 0.25% (95% CI, 0.12%-0.53%) for AA pa-
tients andWApatients, respectively.Ten-year estimates for in-
cidence of non-TNBC were 1.76% (95% CI, 1.27%-2.43%) and
2.85% (95% CI, 2.30%-3.55%) for AA patients and WA pa-
tients, respectively.
Discussion
Triple-negative breast cancer has become a surrogate for the
aggressive basal breast cancer subtype in clinical practice,2 is
amarkerofhereditarybreastcancersusceptibility, ismorecom-
mon among AA women, and has different risk factors. Mul-
tiple pregnancies, for example, reduce the likelihood of de-
velopingER-positive breast cancer, butmultiparity appears to
increase the risk of TNBC.2
Benign breast disease that results inmultiple biopsies is a
well-establishedbreastcancer risk factorand isakeyelementof
Table 2. Distribution of Phenotypes Among PatientsWhoDeveloped Subsequent Invasive Breast Cancer
Subtype
No. (%)
P Value
African American Patients
(n = 66)
White American Patients
(n = 94)
ER+ and/or PR+, ERBB2- 41 (62.1) 70 (74.5)
.01
ER+ and/or PR+, ERBB2+ 6 (9.1) 11 (11.7)
ER-, PR-, ERBB2+ 3 (4.5) 6 (6.4)
ER-, PR-, and ERBB2- 16 (24.2) 7 (7.4) Abbreviations: ER, estrogen receptor;
PR, progesterone receptor.
Table 1. Clinicopathologic Characteristics of Patients DiagnosedWith Subsequent Invasive Breast Cancera
Variable
No. (%)
P Value
African American
Patients
(n = 73)
White American
Patients
(n = 111)
Age at diagnosis of breast cancer, mean (SD) 61.6 (9.4) 61.9 (9.2) .73
Length of time between diagnosis of BBD and breast
cancer, mean (SD), y
6.9 (4.4) 6.2 (3.8) .23
Estrogen receptor
Positive 49 (70.0) 90 (83.3)
.04Negative 21 (30.0) 18 (16.7)
Missing 3 3
Progesterone receptor
Positive 43 (65.6) 85 (79.2)
.009Negative 27 (34.4) 22 (20.8)
Missing 3 4
ERBB2
Positive 9 (13.6) 17 (17.9)
.47Negative 57 (86.6) 78 (82.1)
Missinga 7 16
AJCC stage
IA 21 (20.8) 30 (21.6)
.77
IB 24 (23.8) 39 (28.0)
IIA 9 (8.9) 11 (7.9)
IIB 11 (10.9) 20 (14.3)
IIIA 3 (3.0) 4 (2.9)
IIIC 1 (1.0) 0
IV 2 (2.0) 5 (3.6)
Missing 2 2
Histologic grade
1 13 (18.8) 30 (27.8)
.08
2 29 (42.0) 48 (44.4)
3 27 (39.1) 30 (27.8)
Missing 4 3
Abbreviations: AJCC, American Joint
Committee on Cancer staging system;
BBD, benign breast disease.
a ERBB2 testing is not routinely
performed for cases of ductal
carcinoma in situ; it became a
standardized component of invasive
breast cancer biomarker assays at
the Henry Ford Health System in
2001.
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theGail individualizedbreast cancer risk-assessmentmodel.8
Benign breast disease without atypia approximately doubles
breast cancer risk.9 Histopathologic indices of abnormal pro-
liferationconferhigher risks: 4- to5-fold relative risk for atypia
and 10-fold relative risk for lobular carcinoma in situ.9-11 Sev-
eral studieshaveconfirmed thatBBD is abreast cancer risk fac-
tor in both AA andWAwomen.12,13
Until recently, studies that correlate BBDwith breast can-
cer risk grouped all phenotypes together. Insights regarding
the diversity of breast cancer prompted scrutiny of BBD and
phenotype-stratified risk. Onemodel of breast cancer patho-
genesis suggests that fibrocystic proliferative changes arepre-
cursors for relatively more indolent patterns, including ER-
positive disease.3 The Mayo Clinic BBD cohort demonstrated
that 84% of 1273 cancers detected among more than 13000
BBD cases were ER-positive.4 Similarly, the Cancer and Ste-
roid Hormone Study found that BBD was associated with in-
creased risk for luminal A breast cancer but not hormone re-
ceptor–negative or TNBC disease.5
Theetiologyof theassociationbetweenTNBCandAAiden-
tity ispoorlyunderstood,butenvironmental, reproductive,and
genetic factors have been proposed.14 The contribution of
germline genetic factors is supported by studies that demon-
strated an increased frequency of TNBC among western sub-
SaharanAfricanwomen, apopulation likely tohave sharedan-
cestry with AA women as a consequence of the colonial
transatlantic slave trade.14,15
Although the majority of cancers that developed in our
cohort of AA andWA patients with BBD were ER positive, AA
identity was a statistically significant risk factor for TNBC.
This finding suggests that African ancestry is not only associ-
ated with a woman’s inherent susceptibility for pathways to
developing TNBC but also relevant in discussions of chemo-
prevention.
As an integrated health care system, HFHS is well suited
to study breast cancer disparities because it comprises mul-
tiple facilities and hospitals that provide care to large indi-
gent aswell as affluent populations indiverse communities of
metropolitan Detroit and southeast Michigan; it also offers a
robust employee-based insuranceplan (HealthAlliancePlan).
Our study revealed thatHFHS’sAAandWApatientswithBBD
receivedorobtained similar caremanagement, follow-up, and
outcomes, providing evidence that thehealth care systemde-
livers equitable quality of care.
Conclusions
To our knowledge, this study is the largest report on TNBC in
the context of racial/ethnic identity and BBD as risk factors.
We acknowledge the limitation of self-reported race/
ethnicity; future research will attempt to account for admix-
ture and risk factors, such as obesity and family history. We
hope that our observations will be reevaluated in other
communities.
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Figure. Rates of Subsequent Breast Cancer for African American and
White American Patients, by Phenotype
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A, Probability of subsequent invasive breast cancer after benign breast disease
(log rank, P = .45). B, Probability of triple-negative breast cancer after benign
breast disease (log rank, P = .004). C, Probability of non–triple-negative breast
cancer after benign breast disease (log rank, P = .048).
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